Skip to main content
Premium Trial:

Request an Annual Quote

Caprion Acquires ImmuneHealth's Immune Monitoring Laboratory

NEW YORK (GenomeWeb) – Caprion Biosciences said today that it has acquired the assets of ImmuneHealth's immune monitoring laboratory for an undisclosed amount.

Caprion said that it will use the laboratory to "expand its immune monitoring offering and strengthen its business partnerships and research collaborations throughout Europe." The acquisition will also allow Caprion to move into new areas including infectious disease and vaccine development.

"This European expansion is a core part of Caprion's strategy to strengthen our competitive positioning and expand our service offering to better support our pharma and biotech clients as part of their global and European clinical trial initiatives," Caprion President and CEO Martin LeBlanc said in a statement. He added that the acquisition also gives the company access to a new network of business partners.

Caprion's business is built around two primary services: its ProteoCarta proteomics platform, and its ImmuneCarta platform for immune system monitoring in drug development.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.